PREVENTion of Clot in Orthopaedic Trauma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 12980
Summary
- Conditions
- Blood Clot
- Trauma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Patients who sustain orthopaedic trauma are at an increased risk of venous thromboembolism (VTE), including fatal pulmonary embolism (PE). Current guidelines recommend low-molecular-weight heparin (LMWH) for VTE prophylaxis in orthopaedic trauma patients. However, emerging literature in total joint ...
Patients who sustain orthopaedic trauma are at an increased risk of venous thromboembolism (VTE), including fatal pulmonary embolism (PE). Current guidelines recommend low-molecular-weight heparin (LMWH) for VTE prophylaxis in orthopaedic trauma patients. However, emerging literature in total joint arthroplasty patients suggests the potential clinical benefits of VTE prophylaxis with aspirin. This trial aims to determine if aspirin is non-inferior to LMWH for thromboprophylaxis in fracture patients.
Tracking Information
- NCT #
- NCT02984384
- Collaborators
- Patient-Centered Outcomes Research Institute
- Investigators
- Principal Investigator: Robert O'Toole, MD University of Maryland, College Park Principal Investigator: Renan Castillo, PhD Johns Hopkins Bloomberg School of Public Health Study Director: Tara Taylor, MPH Johns Hopkins Bloomberg School of Public Health Study Director: Katherine Frey, PhD, MPH, RN Johns Hopkins Bloomberg School of Public Health
Get Well Soon